Glucose Clamping Using the Biostator GCIIS

Ca, Verdonk; Cha, Ra Ri; Re, Westland; Rl, Nelson; Je, Gerich

doi:10.1055/s-2007-996224

Cited by 53 publications

(21 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the Biostator a mean CV of the BG concentration of 5.9 ± 0.5% was observed in a euglycemic clamp study in healthy people. 24 The present 39 ClampArt clamps resulted in a slightly lower CV at the target level of 5.5 ± 2.1%. c. Accuracy (as well as trueness and precision) refers to the quality of the measurement, not to the quality of control.…”

Section: Discussionmentioning

confidence: 58%

How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

Benesch

Heise

Klein

et al. 2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background: There are no widely accepted parameters to assess the quality of glucose clamps. Thus, we selected different parameters describing clamp quality. These parameters were then evaluated in glucose clamps carried out with ClampArt, a novel CE-marked, state-of-the-art fully automated glucose clamp device employing continuous blood glucose (BG) measurements and minute-by-minute adaptations of glucose infusion rate (GIR).Methods: Thirty-nine glucose clamps were performed in 10 healthy and 29 subjects with type 1 diabetes (T1DM) (total duration 583 h). ClampArt-based BG measurements were compared with those obtained with a laboratory reference method. Clamp quality was assessed by 5 parameters: (1) difference (mg/dl) of all paired BG measurements of ClampArt versus reference method ("trueness"), (2) coefficient of variation (CV, %) of ClampArt's BG measurements at target clamp level ("precision"), (3) mean absolute relative difference (MARD, %) at target clamp level ("accuracy"), (4) difference (mg/dl) between ClampArt and target BG ("control deviation"), and (5) percentage operational time ("utility"). Results:ClampArt-based BG measurements showed a trueness of 1.2 ± 2.5 mg/dl. CV and MARD at target BG were 5.5 ± 2.1% and 5.3 ± 2.3%, respectively. There were only small deviations from target level (1.2 ± 1.6 mg/dl). Operational time was as high as 95.4% ± 4.1% (means ± SD). Conclusions:The selected parameters seem to be adequate to characterize clamp quality. The novel, fully automated clamp device ClampArt achieves high clamp quality, which in future trials should be compared with other (automated and manual) clamp methods.

show abstract

Section: Discussionmentioning

confidence: 58%

How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

Benesch

Heise

Klein

et al. 2015

J Diabetes Sci Technol

View full text Add to dashboard Cite

show abstract

“…The improve ment in tissue insulin sensitivity demonstrated using the clamp technique may explain the evolution of the insulin need. This technique is now routinely used and results are reproducible [7,8]. We demonstrated for each steady state o f the clamp an improvement in glucose consump tion for similar hyperinsulin levels.…”

Section: Discussionmentioning

confidence: 83%

“…Tissue insulin sensitivity was measured by the glucose clamp technique as described by De Fronzo et al [6] and modified by Verdonk et al [7] and us [8]. The test was performed before begin ning the dietary treatment and after 3 months o f diet.…”

Section: Tissue Insulin Sensitivitymentioning

confidence: 99%

Low-Protein, Low-Phosphorus Diet and Tissue Insulin Sensitivity in Insulin-Dependent Diabetic Patients with Chronic Renal Failure

Gin¹,

Aparicio²,

Potaux³

et al. 1991

Nephron

View full text Add to dashboard Cite

Tissue insulin sensitivity was measured by the glucose clamp technique in 8 uremic insulin-dependent diabetic patients before and after 3 months on a low-protein diet (LPD) providing daily 35 kcal/kg body weight, 60% of the caloric supply being obtained from carbohydrates. An improvement in tissue insulin sensitivity was observed for each steady state of the clamp and daily insulin requirements decreased significantly from 38.3 ± 3.2 to 28.2 ± 2.5 units (p < 0.01) in spite of an increased carbohydrate intake. It is suggested that LPD lowers the production and accumulation of uremic toxins interfering with insulin sensitivity.

show abstract

“…Along with insulin infusion and to avoid hypoglycemia, variable amounts of glucose were infused according to the principles of the euglycemic glucose clamp method first described by De Fronzo et al [6] and applied to the Biostator by Verdonk et al [7], The rate of glucose infusion was automatically adjusted by algorithms of the Biostator. Glucose was infused as a 30% solution to which 0.26 mEq KCl/ml was added to prevent hypokalemia.…”

Section: Experimental Designmentioning

confidence: 99%

Pharmacological Doses of Oxytocin Affect Plasma Hormone Levels Modulating Glucose Homeostasis in Normal Man

Paolisso

Sgambato²,

Passariello³

et al. 1988

Horm Res

View full text Add to dashboard Cite

Phramcological doses of oxytocin administered in basal conditions evoked a rapid surge in plasma glucose and glucagon levels followed by a later increase in plasma insulin and adrenaline levels. The effects of oxytocin on plasma glucagon and adrenaline levels were potentiated by hypoglycemia. When the endogenous pancreas secretion was suppressed by cyclic somatostatin (150 µg/h) and exogenous glucagon (3.5 µg/h) and insulin (0.2 mU/kg·min) were both replaced, oxytocin (0.2 U/min) evoked a transient but significant increase in plasma glucose levels suppressing the glucose infusion rate (GIR) in the first 60 min. On the contrary at higher insulin infusion rate (0.6 mU/kg · min) plasma glucose levels and GIR remained unaffected throughout the study. Oxytocin seems also to potentiate glucose-induced insulin secretion as evidenced by hyperglycemic glucose clamp. In conclusion, pharmacological doses of oxytocin seem to exert a prevalent hyperglycemic effect by a combined action at the liver site (as glycogenolytic agent) and at the endocrine pancreas (as a stimulatory agent of A cell secretion).

show abstract

Glucose Clamping Using the Biostator GCIIS

Cited by 53 publications

References 3 publications

How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

Low-Protein, Low-Phosphorus Diet and Tissue Insulin Sensitivity in Insulin-Dependent Diabetic Patients with Chronic Renal Failure

Pharmacological Doses of Oxytocin Affect Plasma Hormone Levels Modulating Glucose Homeostasis in Normal Man

Contact Info

Product

Resources

About